Partner
and access,
Daniel’s practice involves representing founders, serial entrepreneurs, emerging companies, family offices and other sophisticated investors on a variety of corporate and financing matters, including venture capital financings, SAFE & convertible debt financings, and other investment and corporate transactions. In his emerging company practice, Daniel navigates clients through all growth milestones, from basic formation to equity administration and founder arrangements, to fundraisings and exits. Additionally, Daniel acts as trusted legal advisor to middle-market clients and venture-backed and private equity fund portfolio companies in a mix of corporate matters, ranging from leading traditional M&A transactions and later-stage financings, strategic combinations and restructurings, to advising on corporate governance, intellectual property, and commercial matters. Prior to joining Reitler Kailas & Rosenblatt, Daniel was a Partner at Strategic Law Partners, a venture capital, corporate and M&A boutique firm, where he worked closely with early-stage companies and investors on a variety of venture capital, corporate and financing matters, and served as outside general counsel to emerging and mature businesses. Among various client engagements, Daniel has advised institutional funds such as Carrick Capital Partners on both control acquisitions and portfolio investments in disruptive technologies, while also acting as a trusted business advisor and transactional counsel to mature specialty consumer brands like Madre Mezcal (specialty spirits brand) and Hello Cake (health and wellness brand). In his SLP career, Daniel helped emerging and growth clients complete numerous financings (ranging from early-stage convertible and SAFE rounds to later stage Series Seed and Series A raises, to venture debt financings), recapitalizations, and key strategic partnerships and commercial transactions, led key add-on acquisitions and follow-on financings for portfolio companies of Aurora Capital (NTS, VLS Recovery Services) and Carrick Capital (Flatiron, Legal Sifter, Akorda) and advised on a number of exit transactions and sales of controlling equity stakes of technology companies to PE funds and strategic acquirers (sale of Boostlingo to Mainsail Equity Partners, $200M sale of Apriso Corp. to Dassault Systems, sale of controlling equity stake in ERP Power to Angeles Equity Partners, sale of Precision Business Solutions to New Capital Partners, and sale of Cicoil to a strategic buyer, as a few examples). From 2004 to 2012, Daniel was a key part of Bingham McCutchen’s Corporate/Private Equity Group in Los Angeles, where he represented private and public companies and private equity and venture capital funds in buy- and sell-side M&A transactions, portfolio investment, corporate governance, and other general corporate matters. Daniel worked with premier private equity and venture capital funds such as Platinum Equity, Gores, Freeman Spogli, Levine Leichtman Capital Partners, Riordan Lewis & Haden, Corridor Capital, Omninet Capital, Vintage Capital and NGEN Partners, as well as strategic acquirers such as Honeywell, University of Southern California and Mitsui. During the course of his Bingham career, Daniel also completed an 18-month part-time in-house secondment with Boston Scientific, where he advised the General Counsel of the Neuromodulation Division and its management on day-to-day legal and commercial matters, including drafting and negotiation of supply chain, customer, distributor, services, and other commercial agreements, implementation of licensing, collaboration and promotional arrangements and developing corporate policies. Daniel’s relationship with Boston Scientific continued through the pandemic.
